S&P 500   3,123.99 (-0.13%)
DOW   27,007.51 (-0.27%)
QQQ   216.31 (+0.44%)
AAPL   291.81 (+1.29%)
FB   196.91 (+0.07%)
MSFT   169.92 (+1.10%)
GOOGL   1,386.51 (+0.01%)
AMZN   1,975.00 (+0.11%)
NVDA   267.61 (+2.12%)
BABA   208.61 (+1.46%)
MU   52.23 (+0.25%)
GE   10.89 (-3.80%)
TSLA   786.45 (-1.68%)
AMD   47.74 (+0.36%)
T   37.24 (-0.29%)
F   7.25 (+0.14%)
NFLX   376.09 (+4.44%)
BAC   30.63 (-1.45%)
DIS   122.70 (-4.28%)
GILD   74.23 (+5.89%)
S&P 500   3,123.99 (-0.13%)
DOW   27,007.51 (-0.27%)
QQQ   216.31 (+0.44%)
AAPL   291.81 (+1.29%)
FB   196.91 (+0.07%)
MSFT   169.92 (+1.10%)
GOOGL   1,386.51 (+0.01%)
AMZN   1,975.00 (+0.11%)
NVDA   267.61 (+2.12%)
BABA   208.61 (+1.46%)
MU   52.23 (+0.25%)
GE   10.89 (-3.80%)
TSLA   786.45 (-1.68%)
AMD   47.74 (+0.36%)
T   37.24 (-0.29%)
F   7.25 (+0.14%)
NFLX   376.09 (+4.44%)
BAC   30.63 (-1.45%)
DIS   122.70 (-4.28%)
GILD   74.23 (+5.89%)
S&P 500   3,123.99 (-0.13%)
DOW   27,007.51 (-0.27%)
QQQ   216.31 (+0.44%)
AAPL   291.81 (+1.29%)
FB   196.91 (+0.07%)
MSFT   169.92 (+1.10%)
GOOGL   1,386.51 (+0.01%)
AMZN   1,975.00 (+0.11%)
NVDA   267.61 (+2.12%)
BABA   208.61 (+1.46%)
MU   52.23 (+0.25%)
GE   10.89 (-3.80%)
TSLA   786.45 (-1.68%)
AMD   47.74 (+0.36%)
T   37.24 (-0.29%)
F   7.25 (+0.14%)
NFLX   376.09 (+4.44%)
BAC   30.63 (-1.45%)
DIS   122.70 (-4.28%)
GILD   74.23 (+5.89%)
S&P 500   3,123.99 (-0.13%)
DOW   27,007.51 (-0.27%)
QQQ   216.31 (+0.44%)
AAPL   291.81 (+1.29%)
FB   196.91 (+0.07%)
MSFT   169.92 (+1.10%)
GOOGL   1,386.51 (+0.01%)
AMZN   1,975.00 (+0.11%)
NVDA   267.61 (+2.12%)
BABA   208.61 (+1.46%)
MU   52.23 (+0.25%)
GE   10.89 (-3.80%)
TSLA   786.45 (-1.68%)
AMD   47.74 (+0.36%)
T   37.24 (-0.29%)
F   7.25 (+0.14%)
NFLX   376.09 (+4.44%)
BAC   30.63 (-1.45%)
DIS   122.70 (-4.28%)
GILD   74.23 (+5.89%)
Log in

NASDAQ:ASLN - ASLAN PHARMACEU/ADR Stock Price, Forecast & News

$1.92
-0.10 (-4.95 %)
(As of 02/26/2020 02:21 PM ET)
Today's Range
$1.90
Now: $1.92
$2.05
50-Day Range
$1.96
MA: $2.22
$2.81
52-Week Range
$0.35
Now: $1.92
$8.18
Volume193,215 shs
Average Volume215,434 shs
Market Capitalization$61.54 million
P/E RatioN/A
Dividend YieldN/A
Beta3.09
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ASLN
CUSIPN/A
CIKN/A
Phone65-6222-4235

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.96 per share

Profitability

Net Income$-42,190,000.00

Miscellaneous

EmployeesN/A
Market Cap$61.54 million
Next Earnings Date3/27/2020 (Estimated)
OptionableNot Optionable

Receive ASLN News and Ratings via Email

Sign-up to receive the latest news and ratings for ASLN and its competitors with MarketBeat's FREE daily newsletter.


ASLAN PHARMACEU/ADR (NASDAQ:ASLN) Frequently Asked Questions

What is ASLAN PHARMACEU/ADR's stock symbol?

ASLAN PHARMACEU/ADR trades on the NASDAQ under the ticker symbol "ASLN."

When is ASLAN PHARMACEU/ADR's next earnings date?

ASLAN PHARMACEU/ADR is scheduled to release their next quarterly earnings announcement on Friday, March 27th 2020. View Earnings Estimates for ASLAN PHARMACEU/ADR.

What price target have analysts set for ASLN?

3 brokers have issued 1 year price targets for ASLAN PHARMACEU/ADR's stock. Their forecasts range from $5.00 to $8.00. On average, they anticipate ASLAN PHARMACEU/ADR's stock price to reach $6.50 in the next year. This suggests a possible upside of 238.5% from the stock's current price. View Analyst Price Targets for ASLAN PHARMACEU/ADR.

What is the consensus analysts' recommendation for ASLAN PHARMACEU/ADR?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ASLAN PHARMACEU/ADR in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ASLAN PHARMACEU/ADR.

Has ASLAN PHARMACEU/ADR been receiving favorable news coverage?

News coverage about ASLN stock has trended somewhat negative this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. ASLAN PHARMACEU/ADR earned a media sentiment score of -1.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for ASLAN PHARMACEU/ADR.

Who are some of ASLAN PHARMACEU/ADR's key competitors?

What other stocks do shareholders of ASLAN PHARMACEU/ADR own?

Who are ASLAN PHARMACEU/ADR's key executives?

ASLAN PHARMACEU/ADR's management team includes the folowing people:
  • Dr. Carl Alan Jason Morton Firth, Chairman & CEO (Age 46)
  • Mr. Kiran Asarpota, VP of Fin. (Age 40)
  • Charlie Hsu, Investor Relations Director
  • Mr. Ben Goodger, Gen. Counsel (Age 56)
  • Chi-Chin Wang, IR & Corp. Devel. Director

When did ASLAN PHARMACEU/ADR IPO?

(ASLN) raised $60 million in an initial public offering on Friday, May 4th 2018. The company issued 7,500,000 shares at a price of $8.05 per share. Leerink Partners and Piper Jaffray served as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers.

Who are ASLAN PHARMACEU/ADR's major shareholders?

ASLAN PHARMACEU/ADR's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Marshall Wace LLP (0.30%), Bank of America Corp DE (0.25%), Virtu Financial LLC (0.17%) and Renaissance Technologies LLC (0.05%).

Which institutional investors are buying ASLAN PHARMACEU/ADR stock?

ASLN stock was acquired by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Bank of America Corp DE, Virtu Financial LLC and Renaissance Technologies LLC.

How do I buy shares of ASLAN PHARMACEU/ADR?

Shares of ASLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ASLAN PHARMACEU/ADR's stock price today?

One share of ASLN stock can currently be purchased for approximately $1.92.

How big of a company is ASLAN PHARMACEU/ADR?

ASLAN PHARMACEU/ADR has a market capitalization of $61.54 million. The company earns $-42,190,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. View Additional Information About ASLAN PHARMACEU/ADR.

What is ASLAN PHARMACEU/ADR's official website?

The official website for ASLAN PHARMACEU/ADR is http://aslanpharma.com/.

How can I contact ASLAN PHARMACEU/ADR?

ASLAN PHARMACEU/ADR's mailing address is 83 CLEMENCEAU AVENUE 12-03 UE SQUARE, SINGAPORE U0, 239920. The company can be reached via phone at 65-6222-4235 or via email at [email protected]


MarketBeat Community Rating for ASLAN PHARMACEU/ADR (NASDAQ ASLN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  155 (Vote Outperform)
Underperform Votes:  186 (Vote Underperform)
Total Votes:  341
MarketBeat's community ratings are surveys of what our community members think about ASLAN PHARMACEU/ADR and other stocks. Vote "Outperform" if you believe ASLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel